These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
17. The diverse landscape of dermatologic toxicities of non-immune checkpoint inhibitor monoclonal antibody-based cancer therapy. Seervai RNH, Friske SK, Chu EY, Phillips R, Nelson KC, Huen A, Cho WC, Aung PP, Torres-Cabala CA, Prieto VG, Curry JL. J Cutan Pathol; 2023 Jan; 50(1):72-95. PubMed ID: 36069496 [Abstract] [Full Text] [Related]
18. Annular lichenoid dermatitis of youth: a separate entity or on the spectrum of mycosis fungoides? Case report and review of the literature. Kazlouskaya V, Trager JD, Junkins-Hopkins JM. J Cutan Pathol; 2015 Jun; 42(6):420-6. PubMed ID: 25732922 [Abstract] [Full Text] [Related]
19. Lichenoid drug eruption on the lower lip caused by anti-PD-1 monoclonal antibody: a case report and literature review. Kan S, Ren H, Gao Z, Dai E, Liu Y, Yang L, Cai Q. Immunotherapy; 2021 Dec; 13(17):1373-1378. PubMed ID: 34632814 [Abstract] [Full Text] [Related]
20. Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy. Wang LL, Patel G, Chiesa-Fuxench ZC, McGettigan S, Schuchter L, Mitchell TC, Ming ME, Chu EY. JAMA Dermatol; 2018 Sep 01; 154(9):1057-1061. PubMed ID: 30027278 [Abstract] [Full Text] [Related] Page: [Next] [New Search]